Clinuvel files European marketing authorisation application for SCENESSE (afamelanotide)
European regulators to evaluate new drug’s safety and efficacy for ‘orphan’ disease erythropoietic protoporphyria (EPP)
08-Feb-2012 -
Clinuvel Pharmaceuticals Limited announced that it has submitted a marketing authorisation application (MAA) for its first-in-class drug SCENESSE® (afamelanotide 16mg implant) to the European Medicines Agency (EMA). The MAA covers the use of SCENESSE® as a prophylactic treatment in adult patients ...
erythropoietic protoporphyria